CDK4 and lung carcinoma: EMT dependence on CDK-4 (cyclin-dependent kinase 4) has also been described in in vitro models, with promising efficacy for CDK4 inhibitors in reducing tumor volume in a murine model with autochthonous mesenchymal-like lung cancer with a KRASG12D mutation (34).